Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
Seshagiri Rao NandulaNabanita KunduHassan B AwalBeda BrichacekMona FakhriNikhila AimallaAdrian ElzarkiRichard L AmdurSabyasachi SenPublished in: Cardiovascular diabetology (2021)
A significant expression of CXCR4 receptor with a concomittant increase in migratory function of CD34+ve cells was observed in CG treated group as compared to placebo group. Gene expression analysis of CD34+ve cells showed an increase in expression of antioxidants (superoxide dismutase 2 or SOD2, Catalase and Glutathione Peroxidase or GPX) and notable endothelial markers (PECAM1, VEGF-A, and NOS3). A significant reduction in glucose and HbA1c levels were observed along with improved systolic and diastolic blood pressure in the CG group. A significant increase in adiponectin (p = 0.006) was also noted in treatment group. Urinary exosomal protein leak in urine, examining podocyte health (podocalyxin, Wilm's tumor and nephrin) showed reduction with CG CONCLUSION: Low dose Canagliflozin has a beneficial effect on CD34+ cell function, serum biochemistry and urinary podocyte specific exosomes in type 2 diabetes.
Keyphrases
- blood pressure
- induced apoptosis
- gene expression
- low dose
- type diabetes
- endothelial cells
- poor prognosis
- left ventricular
- cell cycle arrest
- binding protein
- healthcare
- nk cells
- public health
- heart failure
- cardiovascular disease
- stem cells
- mesenchymal stem cells
- insulin resistance
- metabolic syndrome
- mental health
- dna methylation
- cell death
- diabetic nephropathy
- oxidative stress
- clinical trial
- signaling pathway
- randomized controlled trial
- blood glucose
- cell proliferation
- amino acid
- phase iii
- newly diagnosed